Tag: Real World Evidence
From Evidence Generation to Market Access: Why Integrated Evidence Planning Is Pharma’s Competitive Advantage Under EU HTA
From Evidence Generation to Market Access: Why Integrated Evidence Planning Is Becoming Pharma’s Competitive Advantage Under EU HTA How cross-functional collaboration, Real-World Evidence, AI, and early planning are reshaping successful market access strategies across Europe. The European pharmaceutical landscape is changing rapidly. Over the past year, discussions around the EU Health Technology Assessment (HTA) Regulation…
DARWIN EU 2.0 & JCA PICO Strategy: Streamlining Multi-State RWE
Mastering DARWIN EU 2.0 Interoperability for JCA Compliance: The Technical Blueprint for Multi-State Real-World Evidence The European market access landscape is undergoing its most profound structural disruption since the centralization of regulatory approvals. The rollout of the European Union Health Technology Assessment (EU-HTA) regulation has effectively shifted the goalposts for pharmaceutical manufacturers. No longer can…
From Unstructured Data to Regulatory Decisions
From Unstructured Data to Regulatory Decisions: How AI Is Redefining Real-World Evidence The New Reality of Real-World Evidence (RWE) Real-World Evidence (RWE) has moved from the periphery of healthcare decision-making to the very center of regulatory, payer, and market access strategies. As regulators, HTA bodies, and healthcare systems increasingly rely on RWE to complement clinical…
AI & Machine Learning in Real-World Evidence
AI & Machine Learning in Real-World Evidence (RWE): Transforming Healthcare Insights Real-World Evidence (RWE) has become a powerful resource for healthcare innovation. It uses real-world data from sources like electronic health records, insurance claims, registries, and patient-reported outcomes to evaluate medical products and patient care. Artificial Intelligence (AI) and Machine Learning (ML) are reshaping how…
Real World Data to Real World Evidence
From Real-World Data to Real-World Evidence: The Role of AI & FDA Relevance in Shaping the Future of Evidence Generation In today’s data-rich healthcare ecosystem, Real-World Data (RWD) is increasingly viewed as a critical asset, but alone, it’s not enough. The real value emerges when RWD is transformed into Real-World Evidence (RWE) that supports regulatory…
Drug Value with RWE and Role of AI in EU’s JCA
Drug Value with Real-World Evidence (RWE): Opportunities, Challenges, and the Role of AI in EU’s Joint Clinical Assessment (JCA) What is Real-World Evidence and Why It Matters in the EU HTA Landscape Real-World Evidence (RWE) refers to health data gathered outside of traditional clinical trials. It comes from sources like electronic health records, patient registries,…
Why Global Health Agencies Are Demanding RWE in 2025
Why Global Health Agencies Are Demanding Real-World Evidence in 2025 And What It Means for Market Access In 2025, healthcare is no longer defined by clinical trial results alone. Across the globe, regulatory bodies and health technology assessment (HTA) agencies are making one thing crystal clear: Real-World Evidence (RWE) is now a non-negotiable requirement for…
How Generative AI & Wearables Transforming RWE and Market Access
How Generative AI and Wearables Are Redefining Real-World Evidence (RWE) and Market Access in 2025 In 2025, the healthcare industry is undergoing a profound transformation, driven by the dynamic convergence of Generative AI and wearable technologies. These innovations are not just influencing how data is gathered they are fundamentally reshaping the way Real-World Evidence (RWE)…
The Future of Pharma
The Future of Pharma: How Real-World Evidence & AI Are Shaping Market Access in 2025 Why 2025 Is the Breakthrough Year for Real-World Evidence (RWE)? In 2025, AI-driven healthcare and real-world data (RWD) are transforming how treatments are evaluated, approved, and accessed across global markets. Traditional clinical trials are no longer enough. Pharma companies are…
